Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial

作者：Onyema Ogbuagu, Onyema Ogbuagu, Sorana Segal-Maurer, Winai Ratanasuwan, Anchalee Avihingsanon, Cynthia Brinson, Kimberly Workowski, Andrea Antinori, Yazdan Yazdanpanah, Benoit Trottier, Hui Wang, Nicolas Margot, Hadas Dvory‐Sobol, Martin S. Rhee, Jared M. Baeten, Jean-Michel Molina, Edwin DeJesus, Gary Richmond, Mezgebe Berhe, Peter Ruane, Gary Ian Sinclair, Kenneth Lichtenstein, Moti Ramgopal, Andrew Wiznia, Kimberly Workowski, William E. Sanchez, Cynthia Brinson, Joseph P. McGowan, Catherine Creticos, Daniel S Berger, David A. Wheeler, Debbie Hagins, Gordon Crofoot, James J. Sims, Olayemi Osiyemi, Theo Hodge, Christine Zurawski, Onyema Ogbuagu, Onyema Ogbuagu, Sorana Segal-Maurer, Winai Ratanasuwan, Anchalee Avihingsanon, Krittaecho Siripassorn, Ploenchan Chetchotisakd, Antonella Castagna, Andrea Antinori, Francesco Castelli, Sylvie Ronot-Bregigeon, Jean-Michel Molina, Yazdan Yazdanpanah, Benoit Trottier, Jason Brunetta, Takuma Shirasaka, Yoshiyuki Yokomaku, Ellen Koenig, Josep Mallolas, Hans‐Jürgen Stellbrink, Chien‐Ching Hung, Mohammed Rassool · 发表于：The Lancet HIV · 年份：2023 · DOI：10.1016/s2352-3018(23)00113-3 · 被引用次数：71 · 研究领域：HIV Research and Treatment、HIV/AIDS drug development and treatment、Cytomegalovirus and herpesvirus research